Articles by Thomas LeBlanc, MD, MA
Drs. Thomas LeBlanc, Jamie Koprivnikar, and Andrew Brunner give their predictions for the future of MDS management.
An expert panel delves into new data regarding the long-term efficacy of luspatercept in MDS.
An expert MDS panel discusses patient reported outcomes, transfusion dependence, and time toxicity.
Discussing the COMMANDS trial and sequencing luspatercept in patients with myelodysplastic syndromes.
How to address ESA failure or ineligibility in patients with MDS...
Results from a real-world analysis of post-ESA treatment outcomes in patients with lower-risk myelodysplastic syndrome.
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.